FT Options’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

FT Options’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-4,150	Closed	-$320K	–	271
2017 Q2	$320K	Buy	+4,150	New	+$294K	0.55%	41
2016 Q2	–	Sell	-15,000	Closed	-$775K	–	410
2016 Q1	$775K	Buy	+15,000	New	+$779K	0.81%	27

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

AssetMark Inc Concord, California $49B AUM 17.78% 1-Year Est. Return

FT Options's XBI Position: Q3 2017 in Review

FT Options sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2017, closing a stake of 4,150 shares — an estimated $320K sold.

FT Options first reported a position in XBI in Q1 2016 and held it in 2 quarters. The position peaked at $775K in Q1 2016. 349 funds tracked by Wall St. Rank hold XBI as of Q3 2017.

FT Options reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2017 after selling out during the quarter.
FT Options sold 4,150 State Street SPDR S&P Biotech ETF shares in Q3 2017, an estimated $320K.
FT Options first reported a position in State Street SPDR S&P Biotech ETF in Q1 2016 and held it in 2 quarters.
FT Options's State Street SPDR S&P Biotech ETF position peaked at $775K in Q1 2016.
349 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.